Dr. Shaheer Khan
Claim this profileColumbia University Medical Center
Studies Melanoma
Studies Eye Cancer
10 reported clinical trials
17 drugs studied
Area of expertise
1Melanoma
Stage IV
GNAQ positive
GNA11 positive
2Eye Cancer
Stage IV
GNAQ positive
GNA11 positive
Affiliated Hospitals
Clinical Trials Shaheer Khan is currently running
IDE196 Combinations
for Solid Tumors
This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including metastatic uveal melanoma (MUM), cutaneous melanoma, colorectal cancer, and other solid tumors. Phase 1 (dose escalation - monotherapy) will assess safety, tolerability and pharmacokinetics of IDE196 via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study. Phase 1 (dose escalation - binimetib combination) will assess safety, tolerability and pharmacokinetics of IDE196 and binimetinib via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study. Phase 1 (dose escalation - crizotinib combination) will assess safety, tolerability and pharmacokinetics of IDE196 and crizotinib via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study. Evaluation of safety and efficacy across multiple doses may be explored in the dose optimization part of the study. Crizotinib monotherapy with crossover to combination cohort may be assessed for safety and to show the contribution of each study drug to anti-tumor activity. As of Protocol Amendment 10, Phase 1, Phase 2 dose expansion in IDE196 monotherapy, and Phase 2 dose expansion of IDE196 in combination with binimetinib have been fully enrolled. There were no patients enrolled in the crizotinib monotherapy cohorts.
Recruiting1 award Phase 1 & 29 criteria
BMS-986340 + Nivolumab/Docetaxel
for Cancer
This trial tests a new drug, BMS-986340, alone and with other cancer treatments (nivolumab and docetaxel) in patients with advanced solid tumors. The goal is to find out if it is safe and effective in treating these cancers.
Recruiting1 award Phase 1 & 26 criteria
More about Shaheer Khan
Clinical Trial Related9 years of experience running clinical trials · Led 10 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Shaheer Khan has experience with
- Nivolumab
- Ipilimumab
- Docetaxel
- BMS-936558-01
- BMS-986340
- BMS-986207
Breakdown of trials Shaheer Khan has run
Melanoma
Eye Cancer
Uveal Melanoma
Skin Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Shaheer Khan specialize in?
Shaheer Khan focuses on Melanoma and Eye Cancer. In particular, much of their work with Melanoma has involved Stage IV patients, or patients who are GNAQ positive.
Is Shaheer Khan currently recruiting for clinical trials?
Yes, Shaheer Khan is currently recruiting for 4 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Shaheer Khan has studied deeply?
Yes, Shaheer Khan has studied treatments such as Nivolumab, Ipilimumab, Docetaxel.
What is the best way to schedule an appointment with Shaheer Khan?
Apply for one of the trials that Shaheer Khan is conducting.
What is the office address of Shaheer Khan?
The office of Shaheer Khan is located at: Columbia University Medical Center, New York, New York 10032 United States. This is the address for their practice at the Columbia University Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.